The call and the levels

First, the trade. Motilal Oswal values Colgate at 40 times its estimated March 2027 earnings, yielding a target of Rs 2,500 — roughly 27 percent above the ruling Rs 1,965. The scrip has ranged between Rs 1,782 and Rs 2,505 over the past year, so the objective sits at the top of that band. This is a premium multiple, but then Colgate is a premium franchise, throwing off a return on equity north of 80 percent.

The opportunity: a category barely out of bed

Colgate's central argument is that near-universal toothpaste penetration masks a badly under-used category — and that the gap between how Indians brush today and how they could is the real growth runway. The behaviour is shifting, slowly but unmistakably.

Management is reframing oral care as part of overall health — noting, for instance, that people with diabetes carry 2.7 times the risk of gum disease — to lift both frequency and dentist engagement. It is candid that changing habits is a gradual, education-led process, so volume-led acceleration will remain progressive rather than sudden.

Four pillars on a common foundation

The strategy rests on four growth pillars, each standing on a shared base of structural enablers — the architecture management laid out at the meet.

Premiumisation: science over sticker price

The premium push is being fought on efficacy, not price tags. Colgate's premium portfolio is compounding about six times faster than the market, and premium toothpaste roughly five times faster than its nearest rival. The flag-bearers are Colgate Total, Visible White Purple — the company's most successful innovation of the past two years, built on colour-correction technology — and the therapeutic brand PerioGard, the only toothpaste endorsed by the Indian Society of Periodontology, whose net sales are approximately doubling each year on dentist-led prescriptions. The Colgate Strong Teeth formulation with Arginine, management notes, delivers eight times better remineralisation than the closest competitor. The aim, crucially, is not merely to trade consumers up but to lift overall category consumption at the same time.

Toothbrushes and the quick-commerce tailwind

Colgate is the No. 1 toothbrush brand across the Rs 10-to-299 spectrum, with a dual engine: rising replacement rates in rural markets at the bottom of the pyramid and booming super-premium demand in cities at the top. Distribution is vast — about 17 lakh directly serviced outlets and 71 lakh in total reach — while modern trade and e-commerce together account for roughly a fifth of category toothpaste sales. The structural surprise is quick commerce, now some 40 percent of Colgate's e-commerce sales and carrying margins about 400 basis points higher than the traditional channel. Palmolive, meanwhile, is a turnaround bet, with a Bombay Shaving Company partnership sharpening its digital and direct-to-consumer execution.

Margins: spending to grow, without giving ground

Colgate is willingly sacrificing near-term margin to fuel growth, lifting brand investment 34 percent to about Rs 250 crore, near 16 percent of sales, in the June quarter — which is why adjusted profit rose only 8 percent against 12 percent revenue growth. Yet the profit engine is unusually sturdy. Gross margin has stepped up from a 65-to-68 percent band in FY21-23 to about 69.7 percent now, and management intends to keep it range-bound even amid heavier advertising, leaning on its Funding the Growth programme, which delivered 4.7 percent of structural savings in FY26. The EBITDA margin already runs about 500 basis points ahead of the next-closest consumer peer, leaving genuine headroom.

Earnings trajectory and the valuation case

Motilal Oswal models sales, EBITDA and profit compounding at about 9, 11 and 11 percent over FY26-28, carrying revenue from Rs 6,040 crore to Rs 7,120 crore and adjusted profit from Rs 1,340 crore to Rs 1,660 crore, with the EBITDA margin firming past 32 percent. Return ratios remain extraordinary, a hallmark of the capital-light franchise. The 40-times multiple applied to March 2027 earnings underpins the Rs 2,500 target — rich, but consistent with a category leader roughly three times its nearest toothpaste rival.

Risks to weigh